Segment and Related Information (Tables)

3 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of Segment Revenue and Operating Income (Loss)

Segment revenue and operating income (loss) were as follows during the periods presented:

	Diagnostics		Other		Total
Three months ended September 30, 2020
Revenues	$	130.5	$	14.7	$	145.2
Depreciation and amortization	16.7		1.0		17.7
Segment operating loss	(0.3)		(39.3)		(39.6)
Three months ended September 30, 2019
Revenues	$	170.4	$	15.9	$	186.3
Depreciation and amortization	16.9		1.3		18.2
Segment operating income (loss)	17.3		(38.2)		(20.9)

	Three months ended September 30,
	2020		2019
Total operating loss for reportable segments	$	(39.6)	$	(20.9)
Unallocated amounts:
Interest income	0.4		0.9
Interest expense	(2.9)		(2.9)
Other	(1.6)		0.6
Loss from operations before income taxes	(43.7)		(22.3)
Income tax benefit	(28.5)		(1.7)
Net loss	(15.2)		(20.6)
Net loss attributable to non-controlling interest	—		—
Net loss attributable to Myriad Genetics, Inc. stockholders	$	(15.2)	$	(20.6)